130

Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Embed Size (px)

Citation preview

Page 1: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 2: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 3: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 4: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 5: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 6: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 7: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 8: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 9: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

July 3, 2008

Page 10: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 11: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

December 18, 2008

Page 12: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

(relative risk of survival, 0.87; 95% confidence interval, 0.65 to 1.15; P =

0.36)

Page 13: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

June 5, 2008

Page 14: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 15: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

October 1, 2009

Page 16: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 17: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

July 10,, 2008

Page 18: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 19: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 20: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 21: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 22: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 23: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 24: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 25: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 26: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 27: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 28: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 29: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 30: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 31: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 32: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 33: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

January 1,, 2009

Page 34: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 35: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 36: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 37: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 38: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 39: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 40: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 41: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 42: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 43: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 44: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Chest 2010;137;544-551

Page 45: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

seven RCT studies that included 11,425 patients.

Page 46: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 47: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 48: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 49: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 50: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 51: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 52: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 53: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 54: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 55: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

JAMA, March 3, 2010—Vol 303, No. 9

Page 56: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 57: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 58: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

JAMA. 2010;303(8):739-746

Page 59: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 60: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 61: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 62: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 63: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 64: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 65: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 66: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

JAMA. 2009;302(18):1977-1984

Page 67: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 68: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

The COIITSS Study InvestigatorsJAMA. 2010;303(4):341-348

Page 69: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 70: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 71: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 72: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 73: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 6

Page 74: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 9

Page 75: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 76: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2010 Vol. 38, No. 4

Page 77: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Avoid

Page 78: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 6

Page 79: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 80: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 2

Total cohort number 66,184

Page 81: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 82: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2010 Vol. 38, No. 3

Page 83: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 84: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 85: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 5

Page 86: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 87: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 88: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 89: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2010 Vol. 38, No. 2

Page 90: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

155/255 survival 61%

Page 91: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 3

Page 92: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 93: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 9

Page 94: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Overall, 22% (n 71,486) of patients developed acute kidney injury

(Stage I: 17.5%; Stage II: 2.4%; Stage III: 2%)

Odds of death associated with AKI in ICU

Page 95: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2010 Vol. 38, No. 2

Page 96: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

The need for early serial IAP monitoring when IAH/ACS risk factors are present

Improving abdominal wall compliance through sedation, analgesia, and pharmacologic paralysis

Evacuating intraluminal contents through nasogastric or rectal decompression

Evacuating abdominal fluid collections via percutaneous drainage

Correcting positive fluid balance through the use of hypertonic fluids, colloids, and careful diuresis

Supporting organ function vasopressors and judicious goal-directed fluid resuscitation to maintain an abdominal perfusion pressure (calculated as mean arterial pressure IAP) 60 mm Hg

Early surgical intervention when IAP exceeds 25 mm Hg

Page 97: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 98: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 2

Page 99: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Score Variables Points

Predisposition COPD or Immunosuppression

1

Age > 70 ys 1

Insult Bacteremia 1

Multilobar opacities on radiograph

1

Response Shock 1

Severe hypoxemia 1

Organ dysfunction Acute renal failure 1

Respiratory distress syndrome

1

Critical Care Medicine: February 2009 - Volume 37 - Issue 2 - pp 456-462

Range 0-8 points

Page 100: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Critical Care Medicine: February 2009 - Volume 37 - Issue 2 - pp 456-462

HOMEHOSPITAL

ICU?CARE

Page 101: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 8

Page 102: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 103: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 104: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 105: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 106: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 107: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 9

Page 108: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 109: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 5

Page 110: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

24%

Page 111: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 1

Page 112: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 113: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2010 Vol. 38, No. 2

Page 114: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 115: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 116: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 4

Page 117: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 118: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 5

Page 119: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 120: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Crit Care Med 2009 Vol. 37, No. 5

Page 121: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality

Total parenteral nutrition X1 Surgery X1 Multifocal Candida colonization X1 Severe sepsis X 2.

Page 122: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 123: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 124: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 125: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 126: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 127: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 128: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 129: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality
Page 130: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality